Every material Form 8-K Regeneron Pharmaceuticals has filed with the SEC since October 31, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Regeneron Pharmaceuticals reported third quarter 2026 total revenues of $5.1 billion, an increase of 36% compared to the same period in 2025. GAAP net income per diluted share rose 35% to $18.45, while non-GAAP diluted EPS grew 70% to $20.07, driven by strong commercial execution and increased Sanofi collaboration revenue.
Total revenues for Q3 2026 increased 36% to $5.1 billion compared to Q3 2025.
GAAP diluted EPS increased 35% to $18.45, and non-GAAP diluted EPS increased 70% to $20.07.
EYLEA HD U.S. net sales grew 62% to $699 million, and global Libtayo net sales rose 51% to $550 million.
Expanded collaboration with Sanofi adding next-generation antibodies, providing a $1.0 billion up-front payment.
Regeneron and Sanofi amended their antibody collaboration on October 1, 2026, to co-develop and co-commercialize four new long-acting antibodies. Sanofi will pay Regeneron a $1.0 billion upfront payment, with up to $7.0 billion more in milestones, and the two companies will share global profits equally. Regeneron also expects a third-quarter 2026 acquired IPR&D charge of about $22 million, or $0.18 per diluted share, and agreed to dismiss a lawsuit against Sanofi.
Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment dated October 1, 2026.
Regeneron is eligible for up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
Regeneron expects a third-quarter 2026 acquired IPR&D charge of about $22 million pre-tax, reducing GAAP and non-GAAP EPS by about $0.18 per diluted share.
Regeneron agreed to dismiss its lawsuit over Sanofi's obligations to provide information on Dupixent commercialization and audit rights.
Regeneron's Compensation Committee granted CEO Leonard Schleifer and CSO George Yancopoulos one-time performance share units effective September 24, 2026, replacing their annual equity awards through 2036. Payouts depend on new product filings, approvals and revenue from new products over a performance period ending December 31, 2035, with a maximum of 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. The filing also discloses that both executives received equity stakes in a newly formed, majority-owned subsidiary that the company says has nominal value and no significant assets.
Grant effective September 24, 2026; performance period runs January 1, 2026 through December 31, 2035
Revenue-based earnout starts at $10 billion of new product annual revenues and the maximum requires about $30 billion
Award caps are 2,700,000 PSUs for the CEO and 2,900,000 PSUs for the CSO; shares are subject to a holding period until February 2036
Both executives received stakes in a new subsidiary formed to explore a non-core business that has not yet commenced operations
Regeneron reported second quarter 2026 total revenues of $4.3 billion, up 17% from a year earlier, with non-GAAP diluted EPS up 11% to $14.29. GAAP net income fell 7% to $1.3 billion and GAAP diluted EPS fell 5% to $12.23, which the company said included a $1.02 per share negative impact from acquired in-process R&D. The company also narrowed or changed several 2026 guidance items, and it fully repaid the Sanofi Development Balance by the end of the quarter.
Total revenues $4.3 billion, up 17%; Dupixent global net sales recorded by Sanofi rose 38% to $6.0 billion
GAAP net income $1.3 billion, down 7%; non-GAAP net income $1.5 billion, up 8%
2026 guidance updated: GAAP gross margin on net product sales now 78%–79% (prior 77%–78%); capital expenditures now $1.030–$1.100 billion (prior $1.100–$1.200 billion)
Company repurchased $1.2 billion of common stock in the quarter and had $2.5 billion remaining under its repurchase programs as of June 30, 2026
Regeneron said its second quarter 2026 results will include an acquired in-process research and development (IPR&D) charge of about $127 million pre-tax, tied to up-front and opt-in payments under collaboration and licensing agreements. The company expects the charge to reduce both GAAP and non-GAAP net income per diluted share by about $1.00 for the quarter. The figures are preliminary and unaudited, and the company does not forecast such charges.
Expected acquired IPR&D charge of about $127 million on a pre-tax basis for Q2 2026
Expected impact of about $1.00 per diluted share on both GAAP and non-GAAP net income
Charge relates to up-front and opt-in payments under collaboration and licensing agreements
Q2 2026 results have not been finalized and remain subject to closing procedures
Regeneron reported first quarter 2026 revenues of $3.6 billion, up 19% from a year earlier, and non-GAAP earnings per share of $9.47, up 15%. GAAP net income fell 10% to $727 million, and GAAP EPS fell 7% to $6.75, which the company said includes a $0.82 negative impact from acquired in-process R&D; the company also cut its full-year 2026 GAAP gross margin guidance and authorized a new $3.0 billion share repurchase program.
Total revenues were $3,605 million, up 19% from $3,029 million in Q1 2025.
GAAP net income was $727 million, down 10%, and GAAP EPS was $6.75, down 7%; non-GAAP EPS was $9.47, up 15%.
Full-year 2026 GAAP gross margin on net product sales guidance was lowered to 77%–78% from 79%–80%; other guidance was unchanged or raised.
The board authorized a new $3.0 billion share repurchase program in April 2026, and a $0.94 per share dividend was declared.
Regeneron said its first-quarter 2026 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $102 million pre-tax. The charge mainly reflects premiums on equity securities purchased and milestone and up-front payments under collaboration and licensing agreements, and is expected to reduce net income per diluted share by about $0.81. The figures are preliminary and unaudited, and the final results may differ.
Expected acquired IPR&D charge: about $102 million pre-tax for the quarter ended March 31, 2026
Expected impact: about $0.81 reduction in GAAP and non-GAAP net income per diluted share
Charge relates to equity securities premiums and collaboration and licensing payments; Regeneron does not forecast such charges
Regeneron reported fourth quarter 2025 total revenues of $3.9 billion, up 3% from a year earlier, while fourth quarter GAAP earnings per diluted share fell 2% to $7.86. For full year 2025, revenues rose 1% to $14.3 billion and GAAP EPS rose 8% to $41.48, and the company also gave full year 2026 financial guidance.
Q4 2025 total revenues were $3,884 million, up 3% from $3,789 million in Q4 2024.
Q4 2025 GAAP EPS was $7.86 versus $8.06; non-GAAP EPS was $11.44 versus $12.07.
Full year 2025 GAAP EPS was $41.48 versus $38.34; full year non-GAAP EPS was $44.31 versus $45.62.
The company repurchased $3.5 billion of its stock in 2025 and declared a $0.94 per share dividend payable March 5, 2026.
At the J.P. Morgan Healthcare Conference on January 12, 2026, Regeneron disclosed preliminary, unaudited fourth-quarter and full-year 2025 information. The company expects an acquired in-process R&D charge of about $19 million pre-tax, reducing both GAAP and non-GAAP diluted EPS by about $0.14, and about $60 million in matching donations to the Good Days retinal disease fund recorded to SG&A. Shareholders should note that the results are not final and remain subject to closing procedures.
Acquired IPR&D charge of about $19 million pre-tax lowers Q4 2025 GAAP and non-GAAP diluted EPS by about $0.14
Matching program contribution of about $60 million tied to donations to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded to SG&A
Company says results are preliminary and unaudited, and actual results may differ; formal 2026 guidance to come with Q4 2025 earnings
About $3.8 billion returned to shareholders in 2025 and about $1.5 billion remaining under the share repurchase program as of December 31, 2025
Regeneron reported third quarter 2025 total revenues of $3.75 billion, up 1% from a year earlier, and GAAP diluted EPS of $13.62, up 18%. Non-GAAP diluted EPS fell 5% to $11.83, and EYLEA franchise U.S. net sales declined 28% to $1.11 billion, while the company narrowed or lowered several full-year 2025 expense guidance ranges and raised its GAAP effective tax rate guidance to approximately 14%.
Total revenues $3.754 billion vs. $3.721 billion in Q3 2024; Dupixent global net sales recorded by Sanofi rose 27% to $4.86 billion.
GAAP net income rose 9% to $1.460 billion, helped by $578 million in net gains on securities; non-GAAP net income fell 12% to $1.287 billion.
Full-year 2025 guidance: GAAP R&D and non-GAAP SG&A ranges lowered; GAAP effective tax rate raised to approximately 14% from 11%–13%.
Board declared a $0.88 per share dividend payable December 5, 2025; $2.156 billion remained available for share repurchases as of September 30, 2025.
Regeneron said its preliminary third quarter 2025 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $83 million before taxes. The charge mainly relates to the previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals under a 2025 license agreement, and is expected to reduce net income per diluted share by about $0.68. The figures are unaudited and not yet final, so actual results could differ.
Expected acquired IPR&D charge of about $83 million pre-tax for the quarter ended September 30, 2025
Charge mainly relates to the $80 million up-front payment to Hansoh Pharmaceuticals Group under the 2025 license agreement
Expected impact of about $0.68 per diluted share on both GAAP and non-GAAP net income
Results are preliminary and subject to financial statement closing procedures
Regeneron reported second quarter 2025 total revenues of $3.68 billion, up 4% from a year earlier, and GAAP earnings per diluted share of $12.81, up 3%. GAAP net income fell 3% to $1.39 billion, and the company raised its full-year 2025 GAAP effective tax rate guidance to 11%–13%.
Total revenues $3.68 billion, up 4%; GAAP net income $1.39 billion, down 3%
Non-GAAP EPS $12.89, up 12%; GAAP EPS $12.81, up 3%
2025 GAAP effective tax rate guidance raised to 11%–13% from 9%–11%; non-GAAP tax rate guidance unchanged at 11%–13%
Company expects delays to pending FDA approvals for EYLEA HD with August 2025 PDUFA dates; FDA issued a Complete Response Letter for odronextamab on July 30, 2025
Regeneron reported first quarter 2025 total revenues of $3.03 billion, down 4% from a year earlier, driven by a 20% drop in net product sales, mainly EYLEA. GAAP diluted EPS rose 16% to $7.27, while non-GAAP diluted EPS fell 14% to $8.22, and the company lowered its full-year 2025 gross margin guidance.
Total revenues $3.03 billion vs. $3.15 billion in Q1 2024; Sanofi collaboration revenue rose 30% to $1.18 billion.
Non-GAAP diluted EPS $8.22 vs. $9.55 a year earlier (down 14%); GAAP diluted EPS $7.27 vs. $6.27 (up 16%).
2025 guidance: GAAP gross margin on net product sales cut to 83%–84% from 84%–85%; non-GAAP to 86%–87% from 87%–88%; capital expenditures narrowed to $850–$950 million.
Repurchased $1.052 billion of stock in Q1 2025; $3.874 billion remained under repurchase programs as of March 31, 2025; quarterly dividend of $0.88 per share payable June 6, 2025.
Regeneron reported fourth-quarter 2024 revenue of $3.79 billion, up 10% from a year earlier, but GAAP diluted EPS fell 21% to $8.06 on unrealized losses on equity securities. Full-year 2024 revenue rose 8% to $14.20 billion and GAAP diluted EPS rose 10% to $38.34. The board started a quarterly cash dividend of $0.88 per share and added a $3.0 billion buyback, bringing total repurchase capacity to about $4.5 billion.
Q4 2024 GAAP net income was $918 million, down 21%; non-GAAP diluted EPS was $12.07, up 2%
Full-year 2024 GAAP net income was $4.413 billion, up 12%, and total revenue was $14.20 billion, up 8%
Dividend of $0.88 per share is payable March 20, 2025 to holders of record on February 20, 2025
Share repurchase capacity is about $4.5 billion after the new $3.0 billion program; the company repurchased $976 million of stock in Q4 2024
Regeneron released preliminary, unaudited fourth-quarter and full-year 2024 figures at the J.P. Morgan Healthcare Conference, showing aggregate U.S. EYLEA net product sales of $6 billion for the year, up 1%. The company also expects a fourth-quarter acquired in-process R&D charge of approximately $14 million pre-tax, which it says will reduce GAAP and non-GAAP net income per diluted share by about $0.11, and notes that results have not been finalized.
EYLEA HD and EYLEA aggregate U.S. net product sales were $6 billion for 2024, up 1%, and $1.5 billion in the fourth quarter of 2024 (preliminary, unaudited).
Expected fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, primarily related to asset acquisitions.
The charge is expected to lower GAAP and non-GAAP net income per diluted share for Q4 2024 by approximately $0.11.
Libtayo exceeded $1 billion in 2024 annual net sales, according to the press release.
Regeneron reported third quarter 2024 revenue of $3.72 billion, up 11% from a year earlier, and GAAP diluted earnings per share of $11.54, up 30%. Non-GAAP diluted EPS rose 8% to $12.46, and the company cut the top end of its non-GAAP SG&A guidance while raising its capital expenditure guidance.
Total revenues rose 11% to $3.72 billion; GAAP net income rose 33% to $1.34 billion.
Non-GAAP diluted EPS rose 8% to $12.46, including an unfavorable $0.43 impact from acquired IPR&D charges.
Repurchased $738 million of stock in the quarter; $2.9 billion remained under the buyback program at September 30, 2024.
Full-year 2024 capital expenditure guidance was raised to $750–$820 million from $700–$740 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Regeneron Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →